Lazcluze (Lazertinib Mesilate Monohydrate)

Lazcluze is an EGFR tyrosine kinase inhibitor used in the management of EGFR‑driven lung cancer.

• EGFR mutation‑positive NSCLC (first‑line): provides targeted tumor control in patients whose tumours harbour sensitizing EGFR mutations.
• EGFR T790M‑positive NSCLC (post‑progression): overcomes resistance after prior EGFR‑TKI therapy.
• Advanced EGFR‑mutated NSCLC (second‑line): offers an oral option when disease progresses on chemotherapy.
• Maintenance therapy after response: helps sustain disease control in responders.
• Combination with chemotherapy (investigational): explored to enhance efficacy in clinical studies.

• Lazertinib mesilate monohydrate binds irreversibly to the ATP‑binding pocket of mutant epidermal growth factor receptor (EGFR) tyrosine kinases, including common sensitizing mutations and the T790M resistance mutation. This covalent inhibition blocks downstream signaling pathways such as MAPK and PI3K/AKT, suppressing tumor cell proliferation and promoting apoptosis in EGFR‑driven cancers.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Diarrhea: watery stools occurring in many patients.
• Rash: acne‑like skin eruptions on the face and trunk.
• Nausea: mild to moderate feeling of stomach upset.
• Decreased appetite: reduced desire to eat.
• Fatigue: generalized tiredness.
• Dry skin: itching or flaking of the epidermis.

Serious or Rare Side Effects

• Interstitial lung disease: inflammatory lung condition that can be life‑threatening.
• Elevated liver enzymes: signs of hepatic injury requiring monitoring.
• QT interval prolongation: may predispose to cardiac arrhythmias.
• Severe skin reactions (e.g., Stevens‑Johnson syndrome): extensive skin detachment.
• Cardiac failure: reduced heart pumping ability.
• Ocular toxicity: visual disturbances or eye inflammation.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Hepatic impairment: consider dose adjustment or increased monitoring of liver function tests.
• Renal impairment: assess kidney function and adjust therapy if needed.
• Cardiac history: evaluate baseline ECG and monitor for QT prolongation.
• Known hypersensitivity: avoid in patients with documented allergy to lazertinib or similar compounds.
• Pregnancy and lactation: risk unknown; avoid use unless benefits clearly outweigh potential risks.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lazcluze may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce drug exposure.
• Concurrent EGFR TKIs: additive toxicity and overlapping adverse effects.
• Antacids containing aluminum or magnesium: can impair oral absorption.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may increase plasma concentrations.
• Warfarin: monitor INR for potential anticoagulation changes.
• Statins metabolized by CYP3A4 (e.g., simvastatin): watch for myopathy or rhabdomyolysis.